IDEAYA Biosciences Inc 30J
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €31.98
- Day Range
- €32.25–32.25
- 52-Week Range
- —–—
- Bid/Ask
- €32.26 / €32.90
- Shares Outstanding
- 96.49M
- Market Cap
- $3.11B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 145
- Website
- https://www.ideayabio.com
Valuation
|
Metric
|
30J
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.94 |
Price/Sales | 14.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
30J
|
|---|---|
Quick Ratio | 10.21 |
Current Ratio | 10.45 |
Interest Coverage | — |
Quick Ratio
30J
Profitability
|
Metric
|
30J
|
|---|---|
Return on Assets (Normalized) | −10.56% |
Return on Equity (Normalized) | −11.50% |
Return on Invested Capital (Normalized) | −15.12% |
Return on Assets
30J
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!D^NK?? | LOCK|wnL>w | $129B | |||
| Moderna Inc
MRNA
| LOCK|%>^!Rx! | LOCK|PT | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#Y@Nz@ | LOCK|@fsY% | $79B | |||
| argenx SE ADR
ARGX
| LOCK|F&DSl@ | LOCK|!n | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%?#C<j | LOCK|>>v | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|V^Fm^$< | LOCK|qNlgG | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cG%b?Qtn | LOCK|yXdM? | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|!!>!?$ | LOCK|H$C | $24B | |||
| Incyte Corp
INCY
| LOCK|$XPpZ#w | LOCK|#? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|W$>Bc# | LOCK|Ny | $14B |
United States